JP2007504159A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504159A5
JP2007504159A5 JP2006524903A JP2006524903A JP2007504159A5 JP 2007504159 A5 JP2007504159 A5 JP 2007504159A5 JP 2006524903 A JP2006524903 A JP 2006524903A JP 2006524903 A JP2006524903 A JP 2006524903A JP 2007504159 A5 JP2007504159 A5 JP 2007504159A5
Authority
JP
Japan
Prior art keywords
compound
halo
alkyl
carrier
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006524903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504159A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/027997 external-priority patent/WO2005039486A2/en
Publication of JP2007504159A publication Critical patent/JP2007504159A/ja
Publication of JP2007504159A5 publication Critical patent/JP2007504159A5/ja
Pending legal-status Critical Current

Links

JP2006524903A 2003-08-28 2004-08-27 プロテインキナーゼ阻害剤としての化合物および組成物 Pending JP2007504159A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49853203P 2003-08-28 2003-08-28
PCT/US2004/027997 WO2005039486A2 (en) 2003-08-28 2004-08-27 Compounds and compositions as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2007504159A JP2007504159A (ja) 2007-03-01
JP2007504159A5 true JP2007504159A5 (cg-RX-API-DMAC7.html) 2007-10-11

Family

ID=34519982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006524903A Pending JP2007504159A (ja) 2003-08-28 2004-08-27 プロテインキナーゼ阻害剤としての化合物および組成物

Country Status (9)

Country Link
US (2) US7338957B2 (cg-RX-API-DMAC7.html)
EP (1) EP1658290A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007504159A (cg-RX-API-DMAC7.html)
CN (1) CN100439365C (cg-RX-API-DMAC7.html)
AU (1) AU2004283093B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414049A (cg-RX-API-DMAC7.html)
CA (1) CA2536535A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06002347A (cg-RX-API-DMAC7.html)
WO (1) WO2005039486A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
WO2006124462A2 (en) * 2005-05-13 2006-11-23 Irm, Llc Compounds and compositions as protein kinase inhibitors
WO2007113505A2 (en) * 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
BRPI0710496A2 (pt) 2006-04-07 2011-08-16 Novartis Ag combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides
EP2540727B1 (en) 2007-08-02 2018-07-25 Millennium Pharmaceuticals, Inc. Sulfamoylating reagent
EP2188292B1 (en) * 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
BRPI0819453A2 (pt) 2007-11-28 2014-10-07 Dana Farber Cancer Inst Inc Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
AU2009206775A1 (en) * 2008-01-22 2009-07-30 Merck Patent Gmbh Protein kinase inhibitors and use thereof
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
US8728763B2 (en) 2009-08-11 2014-05-20 Response Genetics Methods, primers, probes and kits useful for the detection of BRAF mutations
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104876879B (zh) * 2015-04-14 2018-05-18 中国科学院合肥物质科学研究院 一种bcr-abl激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
NZ510588A (en) * 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
US6610688B2 (en) * 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2009532360A5 (cg-RX-API-DMAC7.html)
ES2871027T3 (es) Inhibidores potentes de la epóxido hidrolasa soluble
ES2213775T3 (es) Metodos de lucha contra las enfermedades infecciosas utilizando bis-benzimidazol dicationicos.
ES2802175T3 (es) Tieno [3,2-d]pirimidinas, furo[3,2,d]pirimidinas y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones del virus sincitial respiratorio
US9974770B2 (en) Formulations comprising triptan compounds
JP2021534124A5 (cg-RX-API-DMAC7.html)
ES2225199T3 (es) Uso de ligandos del receptor ep4 en el tratamiento del dolor neuropatico.
JP2012523415A5 (cg-RX-API-DMAC7.html)
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
JP2001526218A5 (cg-RX-API-DMAC7.html)
BRPI0509795A (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso do composto ou sal farmacologicamente aceitável do mesmo, e, método para promover osteogênese, supressão de ressorção óssea e/ou melhoramento da densidade óssea
JP2003509349A5 (cg-RX-API-DMAC7.html)
JP2009523724A5 (cg-RX-API-DMAC7.html)
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
JP2009521494A5 (cg-RX-API-DMAC7.html)
JP2010510234A5 (cg-RX-API-DMAC7.html)
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
KR20200039029A (ko) 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
DK1427708T3 (da) Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
ES2262689T3 (es) Composicion que contiene un antagonista del receptor de angiotensina ii y un diuretico y su uso para el tratamiento de la hipertension.
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
HU211666A9 (en) Antiviral compounds
HRP20110938T1 (hr) Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora
BR0100946A (pt) Metabólitos de hexahidropirazolo[4,3-c] piridina
JP2013518036A5 (cg-RX-API-DMAC7.html)